Search results
Results from the WOW.Com Content Network
Dr Searle added: “These drugs are a huge breakthrough in this type of cancer, allowing patients without standard treatment options to achieve remission, in many cases for months or years.
A “potent” drug taken once a day can cut the risk of dying from lung cancer by half, according to a new study that scientists hope signals a major breakthrough in tackling the disease ...
AOH1996 was created to target a post-translationally modified isoform of PCNA, termed caPCNA, which is preferentially found in cancer cells. PCNA is crucial in the body for DNA repair , but targeting it is difficult because of its role in healthy cells.
Tisagenlecleucel is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; or adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma ...
Walker’s regular injections may soon come to an end, thanks to a pill developed across the street from the hospital in Donald McDonnell’s cancer biology lab. The Food and Drug Administration ...
Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8 + T cells and NK cells. [1] [2] It is being developed by Nektar Therapeutics.
For premium support please call: 800-290-4726 more ways to reach us
In the United States, Janssen received breakthrough therapy designation for talquetamab in June 2022, for the treatment of adults with relapsed or refractory multiple myeloma, who have previously received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. [17]